Awarded the Merck Group Special Prize for Innovation in Personalized Oncology.
Odimma Therapeutics was honored at BioFIT 2022, Europe’s leading partnering event dedicated to technology transfer, biotechnology innovation and academia-industry collaborations, by receiving the Merck Group Special Prize Awardduring the prestigious Start-up Slams competition.
The distinction recognized Odimma as one of Europe’s most promising biotechnology innovators, highlighting the company’s breakthrough approach to personalized cancer immunotherapy and its potential to reshape the future of precision oncology.
Recognition for a Next-Generation Immunotherapy Platform
BioFIT brings together leading pharmaceutical companies, investors, academic institutions and emerging biotech innovators to identify technologies capable of transforming patient care.
Among the many innovative projects presented during the 2022 edition, Odimma Therapeutics stood out for its proprietary platform combining AI-assisted neoantigen selection, synthetic DNA technologies and personalized immune activation strategies to develop individualized cancer immunotherapies.
Receiving the Merck Group Special Prize underscores the scientific originality and clinical potential of Odimma’s platform while reinforcing its position within Europe’s rapidly expanding biotechnology ecosystem.
Innovation Driving Precision Oncology
Odimma’s technology is designed to harness each patient’s own immune system by targeting tumor-specific neoantigens—unique molecular signatures expressed by cancer cells but absent from healthy tissue.
This personalized approach aims to generate highly specific anti-tumor immune responses while addressing many of the limitations associated with conventional immunotherapy strategies.
By integrating advanced genomics, synthetic biology and scalable manufacturing technologies, Odimma is building a platform capable of delivering individualized therapeutic solutions across multiple oncology indications.
Strengthening Scientific and Industrial Credibility
Recognition by BioFIT and the Merck Group represents an important milestone in Odimma’s development journey.
Beyond validating the company’s scientific vision, the award reflects growing interest from the biotechnology community in next-generation personalized immunotherapy platforms capable of addressing significant unmet medical needs.
As Odimma continues advancing its clinical programs and strategic partnerships, this recognition further reinforces its commitment to developing innovative therapies designed to transform the treatment of difficult-to-treat cancers.
Looking Ahead
The BioFIT 2022 award highlights Odimma Therapeutics’ ambition to become a leading player in precision oncology by combining cutting-edge science with scalable industrial technologies.
The company remains focused on accelerating the development of personalized immunotherapies that harness the patient’s own immune system to deliver more targeted and effective cancer treatments for the future.
